John A. Johnson, MD, MBA: On the managed care side, again, the part we play is to make the medications available. As I stated earlier, there are 12 different classes of oral antidiabetic medications. Insulin [is available] as an injectable medication, [and] the GLP-1s (glucagon-like peptide-1s) are also available.
You’ve got a lot of different medications available, so access to the medications is the part that we would play [a role in] as a health plan. Then, [as a health plan, we provide] wraparound support to augment the medical cocktail—meaning the disease management, the nutrition counseling, and the personal health coach, as well as the nurses that help with meal planning.
That’s how we play our role. If you look at both standards, whether it’s the ADA (American Diabetes Association) or the AACE (American Association of Clinical Endocrinologists), both start with lifestyle modifications. Both start with single-drug therapy. From there, it requires surveillance every 3 months to ensure that you’re checking the patient’s—our member’s—HbA1C (glycated hemoglobin). Again, getting that HbA1C to goal, which would be below 7 for the ADA and below 6.5 for the AACE, and monitoring for hypoglycemia, of course, [is important].
Our hope is that the provider community will use the guidelines that we make available on WellCare.com. [In addition], other managed care companies do the same thing. They have clinical practice guidelines that they make available, and those guidelines are used because they’re evidence-based—they’re connected to recommendations from the medical societies, from the CDC (Centers for Disease Control and Prevention), the NIH (National Institutes of Health), and all of the other approved entities in the United States. Just using those tools that are available [can] enhance the management of your diabetics.
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More